Rosetta Genomics Launches Oncology Sales Team

Approximately one-third of all cancer Rosetta Stonepatients are diagnosed with metastases,xttwx0613 and a large proportion of those cases may have metastases whose primary origin is uncertain even after extensive testing. discount rosetta stone The use of Rosetta\'s miRview™ mets and mets assays may assist physicians to rule out or rule in several suspected origins, as well as offer physicians new origins to explore. Identifying the primary cancer is becoming more important as an increasing number of targeted treatment options specific to certain cancers and tumor types have become available for use by treating clinicians.\"We are very excited to launch our first company-led U.S. commercial effort for our microRNA-based diagnostic tests. This commercial effort marks an important transformation for Rosetta from a rosetta stone cheap research and development focused entity to a fully-integrated biopharmaceutical company with a growing commercial presence. Our near term strategy is to focus Rosetta Stone Hindi our resources on commercializing the miRview™ mets tests as they address an important unmet medical need. With approximately 200,000 CUP and difficult to diagnose metastatic cancer patients per year in the United States, this likely represents our largest near-term market opportunity. Our marketing efforts will continue to be supported by the on-going clinical validation of our tests and underlying microRNA technology, such as the recently published data by M. D. Anderson researchers in Clinical Cancer Research which showed our miRview™ mets test to accurately identify the tumor of origin in CUP patients. In addition, we have several clinical studies validating the accuracy of our microRNA diagnostic tests accepted for poster presentations at the upcoming annual meeting of the American Society of Clinical Oncologists,\" commented Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. \"As evidenced by the M. D. Anderson data and further corroborated by similar findings in a published study by researchers at the University of Heidelberg, our miRview™ mets test has more validated data in true CUP patients than any of our competitors\' tests.\"Cancer of unknown primary (CUP) origin is the diagnosis when metastatic cancer is Rosetta Stone Italian found but the place where the cancer began (the primary site) cannot be determined. According to the U.S. National Cancer Institute, about 2 to 4 percent of all cancer patients have a cancer whose primary site is never identified. Identifying the primary tumorcheap rosetta stone site is important because knowing its location and type often helps doctors plan the best treatment. Treatment that is specific to the suspected type of cancer is likely to be more effective.